Shuang-Feng Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuang-Feng Huang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Chang-Hong Ren
Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China
1 shared publicationCong Han
Department of Neurosurgery, the Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China
1 shared publicationJia-Li Xu
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
1 shared publicationNathan Sim
Department of Neurosurgery, Wayne State University, Detroit, USA
1 shared publication- Sijie Li
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
1 shared publication Wen-Bo Zhao
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 July 2024
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (9) , 925-934
Remote ischemic conditioning prevents ischemic cerebrovascular events in children with moyamoya disease: a randomized controlled trial
Background: Moyamoya disease (MMD) is a significant cause of childhood stroke and transient ischemic attacks (TIAs). This study aimed to assess the safety and efficacy of remote ischemic conditioning (RIC) in children with MMD. Methods: In a single-center pilot study, 46 MMD patients aged 4 to 14 years, with no history of reconstructive surgery, were randomly assigned to receive either RIC or sham RIC treatment twice daily for a year. The primary outcome measured was the cumulative incidence of major adverse cerebrovascular events (MACEs). Secondary outcomes included ischemic stroke, recurrent TIA, hemorrhagic stroke, revascularization rates, and clinical improvement assessed using the patient global impression of change (PGIC) scale during follow-up. RIC-related adverse events were also recorded, and cerebral hemodynamics were evaluated using transcranial Doppler. Results: All 46 patients completed the final follow-up (23 each in the RIC and sham RIC groups). No severe adverse events associated with RIC were observed. Kaplan–Meier analysis indicated a significant reduction in MACEs frequency after RIC treatment [log-rank test (Mantel–Cox), P = 0.021]. At 3-year follow-up, two (4.35%) patients had an ischemic stroke, four (8.70%) experienced TIAs, and two (4.35%) underwent revascularization as the qualifying MACEs. The clinical improvement rate in the RIC group was higher than the sham RIC group on the PGIC scale (65.2% vs. 26.1%, P < 0.01). No statistical difference in cerebral hemodynamics post-treatment was observed. Conclusions: RIC is a safe and effective adjunct therapy for asymptomatic children with MMD. This was largely due to the reduced incidence of ischemic cerebrovascular events. Graphical
- 1 July 2024
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (9) , 925-934
Open AccessRemote ischemic conditioning prevents ischemic cerebrovascular events in children with moyamoya disease: a randomized controlled trial
Background: Moyamoya disease (MMD) is a significant cause of childhood stroke and transient ischemic attacks (TIAs). This study aimed to assess the safety and efficacy of remote ischemic conditioning (RIC) in children with MMD. Methods: In a single-center pilot study, 46 MMD patients aged 4 to 14 years, with no history of reconstructive surgery, were randomly assigned to receive either RIC or sham RIC treatment twice daily for a year. The primary outcome measured was the cumulative incidence of major adverse cerebrovascular events (MACEs). Secondary outcomes included ischemic stroke, recurrent TIA, hemorrhagic stroke, revascularization rates, and clinical improvement assessed using the patient global impression of change (PGIC) scale during follow-up. RIC-related adverse events were also recorded, and cerebral hemodynamics were evaluated using transcranial Doppler. Results: All 46 patients completed the final follow-up (23 each in the RIC and sham RIC groups). No severe adverse events associated with RIC were observed. Kaplan–Meier analysis indicated a significant reduction in MACEs frequency after RIC treatment [log-rank test (Mantel–Cox), P = 0.021]. At 3-year follow-up, two (4.35%) patients had an ischemic stroke, four (8.70%) experienced TIAs, and two (4.35%) underwent revascularization as the qualifying MACEs. The clinical improvement rate in the RIC group was higher than the sham RIC group on the PGIC scale (65.2% vs. 26.1%, P < 0.01). No statistical difference in cerebral hemodynamics post-treatment was observed. Conclusions: RIC is a safe and effective adjunct therapy for asymptomatic children with MMD. This was largely due to the reduced incidence of ischemic cerebrovascular events. Graphical